US5084556A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
Assignee: Genetics Institute LLC
•
Filing: 1990-06-28
•
Granted: 1992-01-28
•
Expires: 2010-06-28
Abstract
Abstract A composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene/M-CSF receptor protein are provided. The composition involves a M-CSF polypeptide cross-linked to a cytotoxic agent capable of crossing into the cytoplasm of the cell bearing the receptor and killing the cell.
Inventors
- 👤 Eugene L. Brown
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:40
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/82; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6425
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
29 words
A therapeutic composition for treating carcinoma characterized by over-expression of the c-fms proto-oncogene/M-CSF receptor gene comprising a M-CSF polypeptide conjugated to a cytotoxic agent and a pharmaceutical carrier therefor.
Claim 2
Dependent Claim
29 words
A therapeutic composition for treating carcinoma characterized by over-expression of the c-fms proto-oncogene/M-CSF receptor gene comprising a M-CSF polypeptide conjugated to a cytotoxic agent and a pharmaceutical carrier therefor.
Claim 3
Dependent Claim
47 words
The composition according to claim 1, wherein said cytotoxic agent is a toxin selected from the group comprising double-chain ricin, ricin A chain, abrin, abrin A chain, modeccin and modeccin A chain, Pseudomonas aeruginosa exotoxin, Cholera toxin, Shigella toxin, E. coli heat labile toxin and Diptheria toxin.
Claim 4
Dependent Claim
23 words
The composition according to claim 1 where said M-CSF polypeptide is linked to said cytotoxic agent by a heterofunctional protein cross linking agent.
Claim 5
Dependent Claim
23 words
The composition according to claim 3 where said cross linking agent is selected from the group consisting of succinimidyl 3-(2-pyridyldithio)propionate) or succinimidyl acetylthiopropriate.
Claim 6
Dependent Claim
16 words
The composition according to claim 1 comprising M-CSF linked through SPDP to a full ricin molecule.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-27 | 1995-07-29 | 1996-01-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-27 | 1999-07-29 | 2000-01-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-27 | 2003-07-29 | 2004-01-28 | $7700.00 | Window Closed / Lapsed |